Effectiveness of Intravenous Immunoglobulin Therapy in Women with Recurrent Spontaneous Abortions and Elevated Pre-conceptional Peripheral Blood CD56+ Natural Killer Cell Percentage.
- Author:
Sun Hwa CHA
1
;
Chan Woo PARK
;
Hae Suk KIM
;
Dong Hee CHO
;
Jin Young KIM
;
Inn Soo KANG
;
Mi Kyoung KOONG
;
Kwang Moon YANG
Author Information
1. Department of Ob/Gyn, Samsung Cheil Hospital, SungKyunkwan University School of Medicine, Seoul, Korea. ykm2955@yahoo.co.kr
- Publication Type:Original Article
- Keywords:
Natural Killer cells;
Intravenous immunoglobulin;
Recurrent spontaneous abortion
- MeSH:
Abortion, Induced;
Abortion, Spontaneous*;
Case-Control Studies;
Female;
Humans;
Immunization, Passive*;
Immunoglobulins*;
Immunoglobulins, Intravenous;
Killer Cells, Natural*;
Medical Records;
Pregnancy;
Pregnancy Outcome;
Retrospective Studies
- From:Korean Journal of Fertility and Sterility
2005;32(2):165-170
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of present study was to evaluate the effectiveness of low-dose intravenous immunoglobulin (IVIg) therapy in women with recurrent spontaneous abortions (RSA) and elevated pre-conceptional peripheral blood CD56+Natural Killer (NK) cell percentage. STUDY DESIGN: Retrospective case control study. MATERIALS AND METHODS: Thirty three women with RSA and elevated pre-conceptional peripheral blood CD56+NK cell percentage who had received low-dose IVIg therapy (400 mg/kg per day, every 4 week, until 20 gestational weeks) were included in this study. Controls were nine women with RSA and elevated pre-conceptional peripheral blood CD56+ Natural Killer (NK) cell percentage who had not received IVIg therapy were included in this study. Medical records of study and control groups were retrospectively analyzed and we compared the successful pregnancy outcomes between two groups. Successful pregnancy outcome was defined as pregnancy ongoing beyond 25 gestational weeks. RESULTS: Age, number of previous abortions, pre-conceptional CD56+NK cell percentage and type of RSA were not statistically different between two groups. Otherwise, twenty-five women who received IVIg therapy (25/33, 75.8%) but, only three women who had not received (3/9, 33.3%) had a successful pregnancy outcome and the rate difference between two groups was statistically significant. CONCLUSION: Based on our study, low-dose IVIg therapy have a effective role in treatment of RSA patients with elevated pre-conceptional peripheral blood CD56+ Natural Killer (NK) cell percentage, but more larger scaled prospective study is needed for available of conclusive evidence.
